| PTCT:PTC Therapeutics Inc | | Charting | News | Options | |||||||||||||
| ||||||||||||||
| ||||||||||||||
| ||||||||||||||
2.41% $1.96
 Markets |
 Portfolio |
| |
| |
|
| |
|
|
|
|||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||
|
| Latest Story |
|
| PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
|
| PR Newswire |
|
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2026, the company approved non-statutory stock options to purchase an aggregate of 10,050 shares of its common stock and 11,870 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 18 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation. |
| Full Story → |
|
| Headline News |
|
| PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 4:30p ET June 17 '26 PR Newswire |
|
|
| PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes |
| 11:16p ET June 15 '26 PR Newswire |
|
|
| PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes |
| 11:16p ET June 15 '26 PR Newswire |
|
| More News → |
| ||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
| July 2 '26. Markets Closed. | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
| Previous data from yesterday, July 1 '26. | ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| Historical Price Performance | ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
Market data provided by 
News provided by   |
1.42%
